The relationship between venous thromboembolism (VTE), dyslipidemia and lipid-lowering
drugs is complex and far from being completely elucidated [1, 2]. Lipid-lowering drugs are a …

Aims The aim is to make a systematic review of the literature to assess the effect of lipid-
lowering drugs on venous thromboembolism (VTE) occurrence. Methods and results …

INTRODUCTION: Several studies have suggested that statins may lower the risk of venous
thromboembolism (VTE), whereas fibrates may increase this risk. However, no studies have …

Venous thromboembolism (VTE) is a common, potentially fatal, and underestimated
condition occurring in 1 per 1000 patients per year worldwide. 1-3 VTE is related either to …

What is the advantage of knowing that statins might prevent venous thromboembolism
(VTE), as suggested by Doggen et al.[1] and others [2, 3](see Table 1)? Even if it can be …

Statin therapy is highly recommended for the primary and secondary prevention of arterial
thrombosis diseases, including coronary and cerebral atherosclerosis. 1 Several studies …

Introduction: Venous thromboembolism (VTE) is an important cause of preventable morbidity
and mortality. Though anticoagulants are effective in preventing VTE, they are associated …

The basic assumption beneath the use of a common therapy for preventing both arterial and
venous thrombosis is that the biology of blood clot formation expresses some overlap, so …

The anti-inflammatory effects of statins have likely not been used to their fullest extent,
particularly in reducing venous thromboembolic events. Current therapy for thrombotic …

Statin drugs have antithrombotic biochemical effects [1]. Two articles in this issue of the
Journal of Thrombosis and Haemostasis report that statin use may prevent venous …